- Home
- GERN
GERN
Geron Corporation
as 02-21-2025 4:00pm EST
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
Upcoming Earnings Alert:
Get ready for potential market movements as Geron Corporation GERN prepares to release earnings report on 26 Feb 2025.
| Founded: | 1990 | Country: | United States |
| Employees: | N/A | City: | FOSTER CITY |
| Market Cap: | 1.5B | IPO Year: | 1996 |
| Target Price: | $6.82 | AVG Volume (30 days): | 12.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.32 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.64 - $5.34 | Next Earning Date: | 02-26-2025 |
| Revenue: | $29,480,000 | Revenue Growth: | 9199.68% |
| Revenue Growth (this year): | 31918.56% | Revenue Growth (next year): | 289.41% |
Latest Geron Corporation News
GERN Breaking Stock News: Dive into GERN Ticker-Specific Updates for Smart Investing
Business Wire
a day ago
Geron to Participate at Upcoming Investor Conferences in March 2025
Business Wire
3 days ago
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MT Newswires
4 days ago
B. Riley Adjusts Geron Price Target to $3.50 From $5.50, Maintains Buy Rating
Insider Monkey
10 days ago
Is Geron Corp. (GERN) the Best Nasdaq Stock Under $5 to Buy?
Business Wire
19 days ago
Geron to Announce Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025
Simply Wall St.
a month ago
Geron (NASDAQ:GERN) shareholder returns have been stellar, earning 169% in 3 years
Business Wire
a month ago
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Insider Monkey
a month ago
Geron Corporation (GERN) Stock: An Under $5 Gem with Biggest Upside Potential
Compare GERN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GERN Geron Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.